Actinium Pharmaceuticals, Inc.
ATNM Healthcare Biotechnology
Actinium Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $90,000.00, up 11.1% from fiscal 2023. In the quarter to June 2026, revenue grew 77,677.8%, EPS grew 504.6% and free cash flow fell 4.91%, each against the same quarter a year earlier.
Follow ATNM
Actinium Pharmaceuticals, Inc. (ATNM) P/E ratio
As of 16 October 2026, Actinium Pharmaceuticals, Inc. (ATNM) trades at a P/E ratio of 3.1×. Over the past ten years it has ranged from 0.0× (June 2026) to 3.9× (September 2026); the current reading is higher than 99% of that period. That is below the Biotechnology industry median of 8.5× and below the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 2.7× | — |
| Sep 2025 | 0.0× | — |
| Dec 2022 | 0.0× | — |
| Sep 2022 | 0.0× | — |
| 6 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ALGS Aligos Therapeutics, Inc. compare | n/m |
| GRDX GridAI Technologies Corp. compare | n/m |
| MGX Metagenomi Therapeutics, Inc. compare | n/m |
| CRVO CervoMed Inc. compare | n/m |
| IRLA Quince Therapeutics, Inc. compare | n/m |
| LIANY LianBio Sponsored ADR compare | 0.0× |
| BCTX BRIACELL THERAP compare | 1.5× |
| ATNM Actinium Pharmaceuticals, Inc. | 3.1× |
| GNTA Genenta Science S.p.A. Unsponsored ADR compare | — |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)